You are here: Industry Insights > Daiichi Sankyo

News List

Daiichi Sankyo launches Tarlige Tablets for pain treatment in Japan biospectrumasia
April 16, 2019
This drug, an α2δ ligand, created by Daiichi Sankyo, was approved for marketing in Japan in January 2019
Daiichi Sankyo Europe, Esperion Announce Validation of MAA for Bempedoic Acid and the Bempedoic Acid/Ezetimibe Fixed Dose Combination Tablet americanpharmaceuticalreview
March 01, 2019
Daiichi Sankyo Europe and Esperion Therapeutics announced the validation of the Marketing Authorisation Application (MAA) for bempedoic acid and the bempedoic acid / ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA).
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase firstwordpharma
February 24, 2019
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced senior-level organizational changes to oversee the realization of the company's long-term vision and strategic priorities, which include delivering seven distinct new molecular en
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] DS-8201 americanpharmaceuticalreview
January 15, 2019
Daiichi Sankyo announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201)....
Daiichi Sankyo takes option on diabetes stem cell start-up pharmaphorum
January 14, 2019
Japan’s Daiichi Sankyo has joined an open innovation research initiative that will try to develop a therapy for type 1 diabetes based on insulin-producing cells.
Daiichi Sankyo receives Japanese marketing approval for two drugs pharmaceutical-technology
January 10, 2019
Daiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively.
Daiichi Sankyo receives Japanese marketing approval for two drugs pharmaceutical-technology
January 10, 2019
Daiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively.....
Daiichi Sankyo Initiates Study of Two Investigational Agents for Patients with AML americanpharmaceuticalreview
December 24, 2018
Daiichi Sankyo announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise......
Daiichi Sankyo claims speedy review for AML drug in Europe pharmaphorum
December 13, 2018
Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline.....
Astellas’ Xospata wins FDA nod in AML, with Daiichi competition looming fiercepharma
December 06, 2018
On an acute myeloid leukemia (AML) roll, the FDA has green-lighted Astellas’ Xospata, also known as gilteritinib. For Astellas, it marks the first step toward challenging Novartis’ Rydapt and likely just a slim head start against Daiichi Sankyo.

Previous page 1 2 3 4 5 6 7 8 Next page